EIKN — Eikon Therapeutics Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $11.9
- 30-Day Move
- -20.7%
- Market Cap
- $536M
- Shares Outstanding
- 53,980,000
- Latest Revenue
- $0
Analyst consensus: Buy · 12 analysts
Eikon Therapeutics Inc
A read-only Alphactor snapshot forEikon Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-17
Topline snapshot
Latest Close
$11.9
30-Day Move
-20.7%
Market Cap
$536M
Shares Outstanding
53,980,000
Latest Revenue
$0
$11.90
-20.7%last 90 delayed daily bars
90D High
$17.40
90D Low
$8.58
Avg Volume
473,894
EIKN is down 20.7% over the last 30 trading days shown on this page.
Latest operating income is $-339M, which helps anchor the headline ratios with an actual earnings figure.
Dark Pool Short %
66.5%
Latest Close
$11.9
30-Day Move
-20.7%
Market Cap
$536M
Shares Outstanding
53,980,000
Latest Revenue
$0
Revenue
$0
Gross Profit
--
Operating Income
$-339M
Net Income
$-324M
Gross Margin
--
Net Margin
--
Current Ratio
--
Debt / Equity
--
Altman Z
-3.24
Distress
Piotroski
2
Weak (0-3)
Cash Conversion
0.58x
Rule of 40
--
Insufficient data
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2023-12-31 | $0 | $-266M | $-242M | $-219M |
| 2024-12-31 | $0 | $-260M | $-244M | $-220M |
| 2025-12-31 | $0 | $-339M | $-324M | $-235M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-02 | Klobuchar Michael A | A | 87,157 | $0.00 |
| 2026-03-02 | Thorner Benjamin Bruno | A | 67,044 | $0.00 |
| 2026-03-02 | Bowie Alfred Lloyd Jr. | A | 67,044 | $0.00 |
| 2026-03-02 | Huffines Robert Luther | A | 25,873 | $0.00 |
| 2026-03-02 | Baynes Roy D. | A | 134,088 | $0.00 |
| 2026-03-02 | PERLMUTTER ROGER M | A | 268,176 | $0.00 |
| 2026-03-02 | FRAZIER KENNETH C | A | 25,873 | $0.00 |
3.92
Consensus
Buy—
—
—
12
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.